SLC5A2 and Hepatic fibrosis: Mendelian randomization demonstrated a causal protective association between SGLT2 inhibition and reduced risk of liver fibrosis/cirrhosis, while in vivo experiments revealed that EMP attenuates hepatic steatosis and liver injury, improves redox balance, and suppresses inflammatory and fibrotic responses.